Identification of MART-1-specific T-cell receptors: T cells utilizing distinct T-cell receptor variable and joining regions recognize the same tumor epitope

David J. Cole, Daniel P. Weil, Peter Shamamian, Licia Rivoltini, Yutaka Kawakami, Suzanne Topalian, Christopher Jennings, Siona Eliyahu, Steven A. Rosenberg, Michael I. Nishimura

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

Tumor-specific cytotoxic T lymphocytes (CTLs) can mediate tumor regression in patients with metastatic melanoma and play a central role in the immune response to cancer. The recent identification of shared melanoma antigens has raised the possibility of a limited melanoma-specific T-cell receptor (TCR) repertoire, but subsequent studies have been controversial and difficult to interpret without knowing which tumor-associated antigens (TAAs) are being recognized by specific TCRs. However, the recent cloning of several melanoma TAAs now allows for the identification of the specifically recognized TAA and its epitope. We evaluated the TCR of two clonal CD8+ CTL lines, A42 and 1E2, from two HLA-A2+ patients with metastatic melanoma. Both CTL lines were MART-1 specific, and both demonstrate reactivity to the same epitope when presented in an HLA-A2.1 context. The TCR genes of the two clones were sequenced. All of the productively rearranged A42 TCR β chain genes were Vβ7/Dβ2.1/Jβ2.7/Cβ2; the TCR α chain genes were Vα21/Jα42/Cα. The 1E2 TCR β chain genes were Vβ3/Dβ1.1/Jβ1.1/Cβ1, and TCR α chains were Vα25/Jα54/Cα. This study is the first report of TCR sequences specific for a melanoma epitope. These TCR clones may be useful for the development of more effective immunotherapies and in studies of the mechanism of T-cell recognition of tumor antigen. They also provide direct evidence that the immune system can provide more than one TCR capable of recognizing a TAA epitope.

Original languageEnglish
Pages (from-to)5265-5268
Number of pages4
JournalCancer Research
Volume54
Issue number20
Publication statusPublished - 1994 Oct 15
Externally publishedYes

Fingerprint

T-Cell Antigen Receptor
Neoplasm Antigens
T-Cell Receptor Genes
Epitopes
T-Lymphocytes
Melanoma
Cytotoxic T-Lymphocytes
Melanoma-Specific Antigens
Neoplasms
Clone Cells
HLA-A2 Antigen
Immunotherapy
Organism Cloning
Immune System

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Cole, D. J., Weil, D. P., Shamamian, P., Rivoltini, L., Kawakami, Y., Topalian, S., ... Nishimura, M. I. (1994). Identification of MART-1-specific T-cell receptors: T cells utilizing distinct T-cell receptor variable and joining regions recognize the same tumor epitope. Cancer Research, 54(20), 5265-5268.

Identification of MART-1-specific T-cell receptors : T cells utilizing distinct T-cell receptor variable and joining regions recognize the same tumor epitope. / Cole, David J.; Weil, Daniel P.; Shamamian, Peter; Rivoltini, Licia; Kawakami, Yutaka; Topalian, Suzanne; Jennings, Christopher; Eliyahu, Siona; Rosenberg, Steven A.; Nishimura, Michael I.

In: Cancer Research, Vol. 54, No. 20, 15.10.1994, p. 5265-5268.

Research output: Contribution to journalArticle

Cole, DJ, Weil, DP, Shamamian, P, Rivoltini, L, Kawakami, Y, Topalian, S, Jennings, C, Eliyahu, S, Rosenberg, SA & Nishimura, MI 1994, 'Identification of MART-1-specific T-cell receptors: T cells utilizing distinct T-cell receptor variable and joining regions recognize the same tumor epitope', Cancer Research, vol. 54, no. 20, pp. 5265-5268.
Cole, David J. ; Weil, Daniel P. ; Shamamian, Peter ; Rivoltini, Licia ; Kawakami, Yutaka ; Topalian, Suzanne ; Jennings, Christopher ; Eliyahu, Siona ; Rosenberg, Steven A. ; Nishimura, Michael I. / Identification of MART-1-specific T-cell receptors : T cells utilizing distinct T-cell receptor variable and joining regions recognize the same tumor epitope. In: Cancer Research. 1994 ; Vol. 54, No. 20. pp. 5265-5268.
@article{6c8332c49eae4fe2b7b25b94251ffb5f,
title = "Identification of MART-1-specific T-cell receptors: T cells utilizing distinct T-cell receptor variable and joining regions recognize the same tumor epitope",
abstract = "Tumor-specific cytotoxic T lymphocytes (CTLs) can mediate tumor regression in patients with metastatic melanoma and play a central role in the immune response to cancer. The recent identification of shared melanoma antigens has raised the possibility of a limited melanoma-specific T-cell receptor (TCR) repertoire, but subsequent studies have been controversial and difficult to interpret without knowing which tumor-associated antigens (TAAs) are being recognized by specific TCRs. However, the recent cloning of several melanoma TAAs now allows for the identification of the specifically recognized TAA and its epitope. We evaluated the TCR of two clonal CD8+ CTL lines, A42 and 1E2, from two HLA-A2+ patients with metastatic melanoma. Both CTL lines were MART-1 specific, and both demonstrate reactivity to the same epitope when presented in an HLA-A2.1 context. The TCR genes of the two clones were sequenced. All of the productively rearranged A42 TCR β chain genes were Vβ7/Dβ2.1/Jβ2.7/Cβ2; the TCR α chain genes were Vα21/Jα42/Cα. The 1E2 TCR β chain genes were Vβ3/Dβ1.1/Jβ1.1/Cβ1, and TCR α chains were Vα25/Jα54/Cα. This study is the first report of TCR sequences specific for a melanoma epitope. These TCR clones may be useful for the development of more effective immunotherapies and in studies of the mechanism of T-cell recognition of tumor antigen. They also provide direct evidence that the immune system can provide more than one TCR capable of recognizing a TAA epitope.",
author = "Cole, {David J.} and Weil, {Daniel P.} and Peter Shamamian and Licia Rivoltini and Yutaka Kawakami and Suzanne Topalian and Christopher Jennings and Siona Eliyahu and Rosenberg, {Steven A.} and Nishimura, {Michael I.}",
year = "1994",
month = "10",
day = "15",
language = "English",
volume = "54",
pages = "5265--5268",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "20",

}

TY - JOUR

T1 - Identification of MART-1-specific T-cell receptors

T2 - T cells utilizing distinct T-cell receptor variable and joining regions recognize the same tumor epitope

AU - Cole, David J.

AU - Weil, Daniel P.

AU - Shamamian, Peter

AU - Rivoltini, Licia

AU - Kawakami, Yutaka

AU - Topalian, Suzanne

AU - Jennings, Christopher

AU - Eliyahu, Siona

AU - Rosenberg, Steven A.

AU - Nishimura, Michael I.

PY - 1994/10/15

Y1 - 1994/10/15

N2 - Tumor-specific cytotoxic T lymphocytes (CTLs) can mediate tumor regression in patients with metastatic melanoma and play a central role in the immune response to cancer. The recent identification of shared melanoma antigens has raised the possibility of a limited melanoma-specific T-cell receptor (TCR) repertoire, but subsequent studies have been controversial and difficult to interpret without knowing which tumor-associated antigens (TAAs) are being recognized by specific TCRs. However, the recent cloning of several melanoma TAAs now allows for the identification of the specifically recognized TAA and its epitope. We evaluated the TCR of two clonal CD8+ CTL lines, A42 and 1E2, from two HLA-A2+ patients with metastatic melanoma. Both CTL lines were MART-1 specific, and both demonstrate reactivity to the same epitope when presented in an HLA-A2.1 context. The TCR genes of the two clones were sequenced. All of the productively rearranged A42 TCR β chain genes were Vβ7/Dβ2.1/Jβ2.7/Cβ2; the TCR α chain genes were Vα21/Jα42/Cα. The 1E2 TCR β chain genes were Vβ3/Dβ1.1/Jβ1.1/Cβ1, and TCR α chains were Vα25/Jα54/Cα. This study is the first report of TCR sequences specific for a melanoma epitope. These TCR clones may be useful for the development of more effective immunotherapies and in studies of the mechanism of T-cell recognition of tumor antigen. They also provide direct evidence that the immune system can provide more than one TCR capable of recognizing a TAA epitope.

AB - Tumor-specific cytotoxic T lymphocytes (CTLs) can mediate tumor regression in patients with metastatic melanoma and play a central role in the immune response to cancer. The recent identification of shared melanoma antigens has raised the possibility of a limited melanoma-specific T-cell receptor (TCR) repertoire, but subsequent studies have been controversial and difficult to interpret without knowing which tumor-associated antigens (TAAs) are being recognized by specific TCRs. However, the recent cloning of several melanoma TAAs now allows for the identification of the specifically recognized TAA and its epitope. We evaluated the TCR of two clonal CD8+ CTL lines, A42 and 1E2, from two HLA-A2+ patients with metastatic melanoma. Both CTL lines were MART-1 specific, and both demonstrate reactivity to the same epitope when presented in an HLA-A2.1 context. The TCR genes of the two clones were sequenced. All of the productively rearranged A42 TCR β chain genes were Vβ7/Dβ2.1/Jβ2.7/Cβ2; the TCR α chain genes were Vα21/Jα42/Cα. The 1E2 TCR β chain genes were Vβ3/Dβ1.1/Jβ1.1/Cβ1, and TCR α chains were Vα25/Jα54/Cα. This study is the first report of TCR sequences specific for a melanoma epitope. These TCR clones may be useful for the development of more effective immunotherapies and in studies of the mechanism of T-cell recognition of tumor antigen. They also provide direct evidence that the immune system can provide more than one TCR capable of recognizing a TAA epitope.

UR - http://www.scopus.com/inward/record.url?scp=0027942629&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027942629&partnerID=8YFLogxK

M3 - Article

C2 - 7522957

AN - SCOPUS:0027942629

VL - 54

SP - 5265

EP - 5268

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 20

ER -